DK1146125T3 - Poxvirus med målrettet infektionsspecificitet - Google Patents
Poxvirus med målrettet infektionsspecificitetInfo
- Publication number
- DK1146125T3 DK1146125T3 DK01400942T DK01400942T DK1146125T3 DK 1146125 T3 DK1146125 T3 DK 1146125T3 DK 01400942 T DK01400942 T DK 01400942T DK 01400942 T DK01400942 T DK 01400942T DK 1146125 T3 DK1146125 T3 DK 1146125T3
- Authority
- DK
- Denmark
- Prior art keywords
- present
- poxviral
- vector
- infection specificity
- targeted infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00440109 | 2000-04-14 | ||
US24608000P | 2000-11-07 | 2000-11-07 | |
EP01440009 | 2001-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1146125T3 true DK1146125T3 (da) | 2005-04-25 |
Family
ID=27223630
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01400942T DK1146125T3 (da) | 2000-04-14 | 2001-04-12 | Poxvirus med målrettet infektionsspecificitet |
DK04077339T DK1516932T3 (da) | 2000-04-14 | 2001-04-12 | Koppevirus med målrettet infektionsspecificitet |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04077339T DK1516932T3 (da) | 2000-04-14 | 2001-04-12 | Koppevirus med målrettet infektionsspecificitet |
Country Status (11)
Country | Link |
---|---|
US (1) | US7354591B2 (ja) |
EP (2) | EP1516932B1 (ja) |
JP (1) | JP2002320475A (ja) |
AT (2) | ATE284970T1 (ja) |
AU (1) | AU784776B2 (ja) |
CA (1) | CA2341356C (ja) |
CY (1) | CY1108478T1 (ja) |
DE (2) | DE60136232D1 (ja) |
DK (2) | DK1146125T3 (ja) |
ES (2) | ES2312918T3 (ja) |
PT (2) | PT1516932E (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
JP4802401B2 (ja) * | 2000-11-07 | 2011-10-26 | トランスジェン・ソシエテ・アノニム | 標的化感染特異性を有するポックスウイルス |
EP1281767A3 (en) * | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
JP4895505B2 (ja) | 2002-05-16 | 2012-03-14 | バヴァリアン・ノルディック・アクティーゼルスカブ | 変異ワクシニアウイルスアンカラ(mva)ゲノム中の挿入部位としての遺伝子間領域 |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
EP1369491A1 (en) * | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
US20030228261A1 (en) * | 2002-06-05 | 2003-12-11 | Aladar Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
US20060121468A1 (en) * | 2002-06-26 | 2006-06-08 | Allnutt F C T | Viruses and virus-like particles for multiple antigen and target display |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
US20050003024A1 (en) * | 2003-03-04 | 2005-01-06 | The Procter & Gamble Company | Regulation of mammalian hair growth |
DE602004018927D1 (de) | 2003-06-18 | 2009-02-26 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
AU2004263274B2 (en) | 2003-07-21 | 2009-11-05 | Transgene S.A. | Novel multifunctional cytokines |
US20070275010A1 (en) * | 2003-09-18 | 2007-11-29 | Mark Feinberg | Mva Vaccines |
EP1947181A4 (en) | 2005-11-24 | 2010-09-22 | Genomidea Inc | MUTANT PARAMYXOVIRUS AND METHOD FOR THE MANUFACTURE THEREOF |
US8052968B2 (en) * | 2006-10-16 | 2011-11-08 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
CN101617052A (zh) | 2007-01-30 | 2009-12-30 | 特兰斯吉恩股份有限公司 | 用于免疫的乳头瘤病毒e2多肽 |
WO2008138533A1 (en) * | 2007-05-14 | 2008-11-20 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
US8003364B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
US8003363B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
FR2925067B1 (fr) * | 2007-12-18 | 2010-01-15 | Agronomique Inst Nat Rech | Vecteurs vaccinaux derives de leporipoxvirus |
SG178254A1 (en) | 2009-08-07 | 2012-03-29 | Transgene Sa | Composition for treating hbv infection |
EA201301173A1 (ru) | 2011-04-15 | 2015-08-31 | Дженелюкс Корпорейшн | Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US9657076B2 (en) | 2012-10-23 | 2017-05-23 | Emory University | GM-CSF and IL-4 conjugates, compositions, and methods related thereto |
SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
CN113347993A (zh) * | 2018-10-22 | 2021-09-03 | 艾赛澳克莱克斯疗法有限责任公司 | 突变牛痘病毒及其用途 |
GB2614309A (en) * | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
WO2024041612A1 (zh) * | 2022-08-24 | 2024-02-29 | 康希诺(上海)生物研发有限公司 | 一种正痘病毒属mRNA疫苗及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07500961A (ja) * | 1990-10-01 | 1995-02-02 | ユニバーシティ オブ コネチカット | 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定 |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US6534051B1 (en) * | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
CA2149889A1 (en) * | 1992-11-20 | 1994-06-09 | Ralph C. Dornburg | Cell-type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins |
AU7097494A (en) * | 1993-06-01 | 1994-12-20 | Targeted Genetics Corporation | Envelope fusion vectors for use in gene delivery |
CA2184354A1 (en) * | 1994-03-04 | 1995-09-08 | Ralph C. Dornburg | Cell-type specific gene transfer using retroviral vectors containing antibody-envelope and wild-type envelope-fusion proteins |
-
2001
- 2001-04-10 CA CA2341356A patent/CA2341356C/en not_active Expired - Fee Related
- 2001-04-12 DK DK01400942T patent/DK1146125T3/da active
- 2001-04-12 US US09/832,899 patent/US7354591B2/en not_active Expired - Fee Related
- 2001-04-12 PT PT04077339T patent/PT1516932E/pt unknown
- 2001-04-12 DK DK04077339T patent/DK1516932T3/da active
- 2001-04-12 PT PT01400942T patent/PT1146125E/pt unknown
- 2001-04-12 DE DE60136232T patent/DE60136232D1/de not_active Expired - Lifetime
- 2001-04-12 ES ES04077339T patent/ES2312918T3/es not_active Expired - Lifetime
- 2001-04-12 DE DE60107746T patent/DE60107746T2/de not_active Expired - Lifetime
- 2001-04-12 AU AU35190/01A patent/AU784776B2/en not_active Ceased
- 2001-04-12 EP EP04077339A patent/EP1516932B1/en not_active Expired - Lifetime
- 2001-04-12 ES ES01400942T patent/ES2232574T3/es not_active Expired - Lifetime
- 2001-04-12 AT AT01400942T patent/ATE284970T1/de active
- 2001-04-12 AT AT04077339T patent/ATE411392T1/de active
- 2001-04-12 EP EP01400942A patent/EP1146125B1/en not_active Expired - Lifetime
- 2001-04-13 JP JP2001153216A patent/JP2002320475A/ja not_active Withdrawn
-
2008
- 2008-11-03 CY CY20081101247T patent/CY1108478T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK1516932T3 (da) | 2008-12-01 |
DE60107746D1 (de) | 2005-01-20 |
DE60107746T2 (de) | 2005-12-01 |
ATE284970T1 (de) | 2005-01-15 |
PT1146125E (pt) | 2005-04-29 |
PT1516932E (pt) | 2009-01-23 |
EP1516932B1 (en) | 2008-10-15 |
AU3519001A (en) | 2001-10-18 |
JP2002320475A (ja) | 2002-11-05 |
DE60136232D1 (de) | 2008-11-27 |
US20030165477A1 (en) | 2003-09-04 |
ES2232574T3 (es) | 2005-06-01 |
ATE411392T1 (de) | 2008-10-15 |
US7354591B2 (en) | 2008-04-08 |
CA2341356A1 (en) | 2001-10-14 |
EP1516932A1 (en) | 2005-03-23 |
CY1108478T1 (el) | 2014-04-09 |
CA2341356C (en) | 2011-10-11 |
EP1146125A1 (en) | 2001-10-17 |
AU784776B2 (en) | 2006-06-15 |
EP1146125B1 (en) | 2004-12-15 |
ES2312918T3 (es) | 2009-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108478T1 (el) | Ιος της ομαδας pox με στοχοθετημενη ειδικοτητα μολυνσης | |
HRP20210766T1 (hr) | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze | |
DE69922958D1 (de) | Hcv hüllproteine partikel : verwendung für therapeutische impfung | |
PT1240325E (pt) | Polipéptidos homólogos de il-17 e il-17r e suas utilizações terapêuticas | |
ATE420160T1 (de) | Modifizierte rekombinante vacciniaviren, verwendungen davon | |
DK1607402T3 (da) | Sammensætninger og fremgangsmåder til tumorbehandling | |
PT1278868E (pt) | Forma mutada de arginina desiminase | |
ATE306555T1 (de) | Replikationsdefizienter adenoviraler tnf vektor | |
MX2021010862A (es) | Arn terapeutico para el cancer de prostata. | |
NO20032818L (no) | Polypeptider | |
ES2329689T3 (es) | Composiciones y procedimientos para el diagnostico de tumores. | |
DE60129069D1 (de) | Hepatitis B Virus Vektoren für Gentherapie | |
WO2003062374A3 (en) | Synthetic genes for malarial proteins and methods of use | |
EA200401505A1 (ru) | Экспрессия генов модифицированного вируса осповакцины ankara с использованием ati-промотора вируса коровьей оспы | |
FI20050753A0 (fi) | Uudet peptidit | |
DK1423525T3 (da) | Rekombinant MVA, der kan eksprimere HCV-strukturantigener | |
WO2003090778A3 (en) | Dna vaccine combined with an inducer of tumor cell apoptosis | |
WO2000069455A3 (de) | Organ-, gewebs- und zellspezifisches immuntherapeutikum für chronische virale infektionen, sowie entzündliche, degenerative und proliferative erkrankungen insbesondere der leber sowie krebs auf der basis von rekombinantem parapoxvirus | |
DE602004032365D1 (de) | Modifizierter cea/b7-vektor | |
DE60134956D1 (de) | Gene differentiell experimiert in brudtkrebs | |
NZ603105A (en) | Detection of mutations in a gene associated with resistance to viral infection, oasi | |
WO2002077193A8 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof |